Contrasting CareDx (CDNA) and CBA Florida (CBAI)
CareDx (NASDAQ:CDNA) and CBA Florida (OTCMKTS:CBAI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.
Risk & Volatility
CareDx has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, CBA Florida has a beta of -0.43, meaning that its stock price is 143% less volatile than the S&P 500.
This table compares CareDx and CBA Florida’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and price targets for CareDx and CBA Florida, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CareDx presently has a consensus target price of $35.00, suggesting a potential upside of 25.40%. Given CareDx’s higher possible upside, analysts plainly believe CareDx is more favorable than CBA Florida.
Earnings and Valuation
This table compares CareDx and CBA Florida’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CareDx||$48.32 million||22.47||-$55.46 million||($0.77)||-36.25|
|CBA Florida||$5.26 million||1.67||$400,000.00||N/A||N/A|
CBA Florida has lower revenue, but higher earnings than CareDx.
Insider and Institutional Ownership
77.0% of CareDx shares are held by institutional investors. 3.4% of CareDx shares are held by insiders. Comparatively, 30.1% of CBA Florida shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
CareDx beats CBA Florida on 7 of the 12 factors compared between the two stocks.
CareDx Company Profile
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics. The Post-Transplant Diagnostics segment develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell free DNA test initially used for kidney transplant patients. The Pre-Transplant Diagnostics segment develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HAL) alleles based on sequence-specific primer technology; Olerup QTYPE, a test kit for sequence based HLA typing; Olerup SBT, a test kit for sequence based HLA typing; and XM-ONE, a test that identifies a patient's antigens against HLA Class I or Class II, as well as antibodies against a donor's endothelium. This segment offers its products directly to customers, as well as through third-party distributors. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
CBA Florida Company Profile
CBA Florida, Inc. does not have significant operations. Previously, the company provided umbilical cord blood and cord tissue stem cell processing and storage to families in the United States. The company was formerly known as Cord Blood America, Inc. and changed its name to CBA Florida, Inc. in May 2018. CBA Florida, Inc. is headquartered in Las Vegas, Nevada.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.